MoonLake Immunotherapeutics (MLTX) CSO sells 150,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

MoonLake Immunotherapeutics Chief Scientific Officer Kristian Reich reported open-market sales of a total of 150,000 Class A ordinary shares associated with him over three days. The shares are owned by JeruCON Beratungsgesellschaft mbH, where he is deemed an indirect beneficial owner.

The indirect holdings sold were 50,000 shares on each of June 15, 16, and 17, 2026, at weighted average prices of about $18.89, $18.70, and $19.43 per share, within price ranges from roughly $18.24 to $19.97. These transactions were carried out under a Rule 10b5-1 trading plan adopted on March 10, 2026.

After these sales, JeruCON’s indirect position is reported as 2,824,551 shares, while Reich also holds 35,389 shares directly, indicating that he retains a substantial equity interest in MoonLake Immunotherapeutics following the transactions.

Insights

Equity market & insider-trading analyst

Routine 10b5-1 plan sales; CSO retains a large remaining stake.

The filing shows 150,000 MoonLake Immunotherapeutics shares sold in the open market over three days by JeruCON Beratungsgesellschaft mbH, an entity for which Chief Scientific Officer Kristian Reich is deemed an indirect beneficial owner under Section 16 rules.

The trades, all coded as open-market sales, occurred around $18.70–$19.43 per share and are explicitly disclosed as executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026. Such pre-arranged plans typically indicate a systematic diversification approach rather than opportunistic timing.

Post-transaction, JeruCON still holds 2,824,551 shares and Reich holds another 35,389 shares directly, so the reported sales represent a minority slice of his visible equity exposure. The absence of derivative positions in this filing suggests the focus here is on common-share liquidity rather than option exercises.

Insider Trade Summary 10b5-1

Net Seller: 150,000 shares ($2,851,000)

Net Sell 4 txns

Insider Reich Kristian

Role Chief Scientific Officer

Sold 150,000 shs ($2.85M)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share	50,000	$19.43	$972K
Sale	Class A ordinary shares, par value $0.0001 per share	50,000	$18.70	$935K
Sale	Class A ordinary shares, par value $0.0001 per share	50,000	$18.89	$945K
holding	Class A ordinary shares, par value $0.0001 per share	--	--	--

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 2,824,551 shares (Indirect, See footnote.); Class A ordinary shares, par value $0.0001 per share — 35,389 shares (Direct, null)

Footnotes (1)

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.66 to $19.12. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.235 to $19.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.915 to $19.97. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 150,000 shares Sale price 17 June 2026: $19.43 per share Sale price 16 June 2026: $18.70 per share +4 more

7 metrics

Shares sold 150,000 shares Total open-market sales in June 2026

Sale price 17 June 2026 $19.43 per share Weighted average price for 50,000-share sale

Sale price 16 June 2026 $18.70 per share Weighted average price for 50,000-share sale

Sale price 15 June 2026 $18.89 per share Weighted average price for 50,000-share sale

Post-sale indirect holdings 2,824,551 shares JeruCON Beratungsgesellschaft mbH holdings after transactions

Direct holdings 35,389 shares Direct Class A ordinary share position as of 15 June 2026

Trading plan adoption date March 10, 2026 Rule 10b5-1 plan governing reported sales

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, indirect beneficial owner, Section 16 of the Securities Exchange Act of 1934, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

indirect beneficial owner regulatory

"may be deemed for purposes of Section 16 ... to be the indirect beneficial owner"

Section 16 of the Securities Exchange Act of 1934 regulatory

"for purposes of Section 16 of the Securities Exchange Act of 1934, as amended"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

Class A ordinary shares financial

"Class A ordinary shares, par value $0.0001 per share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reich Kristian

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG V8 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	06/15/2026		S(1)		50,000	D	$18.89(2)	2,924,551	I	See footnote.(3)
Class A ordinary shares, par value $0.0001 per share	06/16/2026		S(1)		50,000	D	$18.7(4)	2,874,551	I	See footnote.(3)
Class A ordinary shares, par value $0.0001 per share	06/17/2026		S(1)		50,000	D	$19.43(5)	2,824,551	I	See footnote.(3)
Class A ordinary shares, par value $0.0001 per share								35,389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.66 to $19.12. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

4. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.235 to $19.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

5. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.915 to $19.97. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) disclose for Kristian Reich?

MoonLake Immunotherapeutics disclosed that Chief Scientific Officer Kristian Reich reported open-market sales of 150,000 Class A ordinary shares. The sales occurred over three days in June 2026 and involved shares owned by JeruCON Beratungsgesellschaft mbH, where he is deemed an indirect beneficial owner.

How many MoonLake Immunotherapeutics (MLTX) shares were sold and at what prices?

A total of 150,000 MLTX Class A ordinary shares were sold, in three blocks of 50,000 shares. Weighted average prices were about $18.89, $18.70, and $19.43 per share, with individual trades executed within disclosed ranges between roughly $18.24 and $19.97.

Were the MLTX insider share sales by Kristian Reich part of a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on March 10, 2026. Such pre-arranged plans automate trading according to preset instructions, often indicating routine portfolio management rather than discretionary market-timing decisions.

Who actually owns the MoonLake Immunotherapeutics (MLTX) shares sold in this Form 4?

The shares are owned by JeruCON Beratungsgesellschaft mbH. The filing explains that Dr. Kristian Reich may be deemed the indirect beneficial owner of JeruCON’s ordinary shares for Section 16 purposes, which is why the transactions appear on his Form 4.

How many MoonLake Immunotherapeutics (MLTX) shares does Kristian Reich hold after these sales?

After the reported sales, JeruCON Beratungsgesellschaft mbH holds 2,824,551 MLTX Class A ordinary shares indirectly associated with Kristian Reich. He also holds 35,389 shares directly, so he continues to have a significant equity interest in MoonLake Immunotherapeutics following the transactions.

Did the MLTX Form 4 report any option exercises or derivative transactions for Kristian Reich?

No. The Form 4 only reports non-derivative transactions in Class A ordinary shares and includes one direct-holding line. The derivativeSummary section is empty, indicating no option exercises, warrant conversions, or other derivative-related transactions were disclosed in this particular filing.